NEWTOWN, Pa., May 24, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies (Nasdaq:HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for gait deficits, is ...
For many people living with multiple sclerosis (MS), walking can become one of the most challenging daily tasks. As many as 3 in 4 people with MS have gait issues caused by factors like loss of muscle ...
Helius Medical Technologies, Inc. announced positive outcomes from its Portable Neuromodulation Stimulator (PoNS) Stroke Registrational Program (SRP), which supports a planned FDA submission for ...
Helius Medical Technologies, Inc. announced that it will present results from its new study on the Portable Neuromodulation Stimulator (PoNS®) at the upcoming Consortium of Multiple Sclerosis Centers ...
--PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy on gait deficit improvement in people with Multiple Sclerosis-- --Statistically ...
NEWTOWN, Pa., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results